Trial Profile
DFN-11 Injection in Episodic Migraine With or Without Aura
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sumatriptan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms RESTOR
- Sponsors Dr Reddys Laboratories
- 23 Jul 2018 Status changed from active, no longer recruiting to completed.
- 01 Jul 2018 Results assessing the safety of Sumatriptan Injection with focus on Triptan Sensations and Injection Site Reactions, presented at the 60th Annual Scientific Meeting of the American Headache Society
- 01 Jul 2018 Results (n=268) presented at the 60th Annual Scientific Meeting of the American Headache Society.